Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 2, 2009, Pages 158-164

  Grossberg, George ^a   Sadowsky, Carl ^b   Förstl, Hans ^d   Frölich, Lutz ^e   Nagel, Jennifer ^c   Tekin, Sibel ^c   Zechner, Stefanie ^c   Ros, Jacqueline ^c   Orgogozo, Jean Marc ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Patch; Rivastigmine; Transdermal

Indexed keywords

PLACEBO; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PHENYLCARBAMATES; TREATMENT OUTCOME; VOMITING;

EID: 67651071488     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31818b1c2c     Document Type: Article

References (21)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403. (Pubitemid 8004505)
2. Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006;67:657-664.
3. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
4. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41:719-739. (Pubitemid 34948194)
5. Mercier F, Lefèvre G, Aaron H-L, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23:3199-3204.
6. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456-467. (Pubitemid 46831690)
7. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:485-491. (Pubitemid 46831693)
8. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23:2705-2713. (Pubitemid 350146408)
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
10. Diagnostic and statistical manual of mental disorders (DSMIV), American Psychiatric Association. 4th ed; 1994.
11. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
13. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32.
14. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
15. Novartis Pharmaceuticals. FDA approved Exelons® Patch label. 2007.
16. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151: 390-396. (Pubitemid 24081459)
17. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705-711. (Pubitemid 26307301)
18. Farlow MR, Small GW, Quarg P, et al. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20:192-197. (Pubitemid 41191637)
19. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract. 2005;59:817-822. (Pubitemid 43904548)
20. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord. 2002;16:49-51.
21. Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11:231-239.